Erschienen in:
25.10.2016 | Gastrointestinal Oncology
How Do We Bridge the West and the East in the Treatment for Gastric Cancer?
verfasst von:
Koichi Suda, MD, PhD, FACS, Yuko Kitagawa, MD, PhD, FACS
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 4/2017
Einloggen, um Zugang zu erhalten
Excerpt
In 2012, gastric cancer (GC) was the fifth most common malignancy and the third leading cause of cancer death in the world.
1 The prevalence of GC remains more common in countries of the Far East, including Japan and Korea, than in countries of the West.
2 Moreover, better overall survival (OS) has been reported in Eastern trials than the Western series (East vs West 5-year OS: 60–70 vs 30–40 %)
3‐
7 Eastern investigators may argue that this difference is attributable to more radical surgery, whereas Western investigators may claim that this difference is attributable to earlier detection and differences in biology.
8,
9 …